In Reply We agree with Drs Friedrich and Burns that prophylaxis against postextubation respiratory failure with NIV or HFNC was more common in the PSV group than in the T-piece group (24.7% vs 18.7%).1 However, the decision to apply prophylaxis was made before randomization, so this difference can only be attributed to chance. We would like to clarify that patients could receive prophylactic NIV or HFNC but not both.
Subirà C, Fernández R. Spontaneous Breathing Trials and Successful Extubation—Reply. JAMA. 2019;322(17):1717. doi:https://doi.org/10.1001/jama.2019.14244
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: